PART I . TNF is a clinical stage pharmaceutical company committed to extending healthy lifespan. TNF is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets, Isomyosamine and Supera-CBD: Isomyosamine is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including (but not limited to) sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, an...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-11 | 2024-12-31 | 0001641172-25-003814 | EDGAR | 133K words |
| 2024-04-01 | 2023-12-31 | 0001493152-24-012533 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010384 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001493152-22-008546 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001493152-21-005129 | EDGAR | — |
| 2020-03-25 | 2019-12-31 | 0001493152-20-004650 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001493152-19-004590 | EDGAR | — |
| 2018-04-03 | 2017-12-31 | 0001493152-18-004626 | EDGAR | — |
| 2017-04-11 | 2016-12-31 | 0001493152-17-003722 | EDGAR | — |
| 2016-03-30 | 2015-12-31 | 0001493152-16-008364 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001493152-25-024320 | EDGAR | 61K words |
| 2025-08-19 | 2025-06-30 | 0001641172-25-024859 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010937 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-046026 | EDGAR | — |
| 2024-08-19 | 2024-06-30 | 0001493152-24-032940 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019976 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041328 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028603 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001493152-23-017488 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031423 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022611 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001493152-22-013927 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-13 | 0001493152-26-010070 | EDGAR | 1K words |
| 2026-01-23 | 0001493152-26-003440 | EDGAR | — |
| 2025-12-09 | 0001493152-25-026798 | EDGAR | — |
| 2025-11-14 | 0001493152-25-023596 | EDGAR | — |
| 2025-10-03 | 0001493152-25-016927 | EDGAR | — |
| 2025-09-26 | 0001493152-25-015774 | EDGAR | — |
| 2025-09-10 | 0001641172-25-027052 | EDGAR | — |
| 2025-09-02 | 0001641172-25-026167 | EDGAR | — |
| 2025-06-06 | 0001641172-25-014103 | EDGAR | — |
| 2025-05-09 | 0001641172-25-009514 | EDGAR | — |
279 total filings indexed. 247 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001321834 |
| Ticker | QCLS |
| Exchange | Nasdaq |
| SIC | 2835: In Vitro & In Vivo Diagnostic Substances |
| Incorporated | DE |
| Website | https://www.qctechnologies.com |
| Listed | 2021-04-19 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/QCLS (~200 tokens, structured JSON with cryptographic provenance)